A Prospective, Multicentre, Open-label Randomised Controlled Study to Investigate the Effectiveness of Pamidronate in the Prevention of Bone Loss in de Novo Renal Transplant Patients.
NCT00738257
·
clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
126
Enrollment
INDUSTRY
Sponsor class
Conditions
Bone Loss
Interventions
DRUG:
Pamidronate
Sponsor
Novartis Pharmaceuticals